Advertisements

GlycoMimetics Inc. (GLYC) Stock Quote

Detailed Quote for GlycoMimetics Inc. (GLYC)
$ 13.00 R     -0.89 (-6.41%) Volume: 3.76m 4:00 PM EDT May 26, 2017
After Hours:  $ 13.10   0.10 (+0.77%) Volume: 8.8k 7:59 PM EDT May 26, 2017
Today 5d 1m 3m 1y more
Last Price
13.00
Change $
0.89
Change %
6.41%
Tick
  
Bid
12.97
Bid Size
500
Ask
13.10
Ask Size
100
Open
13.43
High
13.67
Low
12.31
Prev Close
13.89
Last Trade
05/26/17
Volume
3.76m
52 Wk Hi
16.9400005
52 Wk Low
3.81999993
Market Cap
320.32m
Ex-Div Date
N/A
Div Rate
N/A
Yield
N/A
Shares
24,640,350
EPS (TTM)
-1.45000004
PE Ratio
N/A
Exchange
NSD
News and Media for GlycoMimetics Inc. (GLYC)
Sector News | Topic News
News for GlycoMimetics Inc. (GLYC)
Fri, May 26, 2017
1:40 PM Therapy Focus - Not Quite The Hammer For Sickle Cell Disease - SeekingAlpha
Thu, May 25, 2017
11:25 AM GycoMimetics' GMI-1271 an Orphan Drug in Europe for AML; shares up 11% - SeekingAlpha
9:25 AM GlycoMimetics' GMI-1271 Receives EU Orphan Drug Designation for Acute Myeloid Leukemia - Business Wire
Wed, May 24, 2017
8:00 AM GlycoMimetics Announces Pricing of Public Offering of Common Stock - Business Wire
Tue, May 23, 2017
5:35 PM After Hours Gainers / Losers - SeekingAlpha
Mon, May 22, 2017
5:36 PM After Hours Gainers / Losers - SeekingAlpha
4:01 PM GlycoMimetics Announces Proposed Public Offering of Common Stock - Business Wire
9:11 AM Premarket Losers as of 9:05 am - SeekingAlpha
Fri, May 19, 2017
12:41 PM Midday Gainers / Losers - SeekingAlpha
12:19 PM 3 Things In Biotech You Should Learn Today: May 19, 2017 - SeekingAlpha
9:18 AM Premarket Gainers as of 9:05 am - SeekingAlpha
Thu, May 18, 2017
2:10 PM GlycoMimetics' (GLYC) CEO Rachel King on Q1 2017 Results - Earnings Call Transcript - SeekingAlpha
12:50 PM Midday Gainers / Losers - SeekingAlpha
9:21 AM Premarket Gainers as of 9:05 am - SeekingAlpha
6:30 AM GlycoMimetics Announces High Overall Response Rates, Low Induction Mortality,\u00A0Promising Initial Survival Outcomes, and Supportive Biomarker Data from Phase 1/2 Trial of GMI-1271 in AML - Business Wire
Wed, May 17, 2017
6:35 PM GlycoMimetics drug candidate gets FDA Breakthrough Therapy designation - SeekingAlpha
5:35 PM After Hours Gainers / Losers - SeekingAlpha
4:10 PM GlycoMimetics' GMI-1271 Receives FDA Breakthrough Therapy Designation for Adult Relapsed/Refractory Acute Myeloid Leukemia - Business Wire
Tue, May 16, 2017
10:41 AM GlycoMimetics: A New Angle On Tackling Chemo Resistance - SeekingAlpha
Fri, May 12, 2017
3:23 PM GlycoMimetics perks up ahead of development update; shares up 24% - SeekingAlpha
More News for GLYC >>

Tags for GlycoMimetics Inc.

Research stocks or mutual funds related to GlycoMimetics Inc. by keywords or tags. Find companies that have a similar focus to GLYC. The keywords below have been associated to GLYC by either user submission or electronic means.